調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

World Pharma Wholesale and Distribution Industry and Market: Trends, Developments and Commercial Predictions 2015-2025

医薬品卸売/流通の世界市場動向及び予測

◆タイトル：World Pharma Wholesale and Distribution Industry and Market: Trends, Developments and Commercial Predictions 2015-2025
◆商品コード：VGAIN5102607
◆調査・発行会社：visiongain
◆発行日：2015年10月
◆ページ数：270
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医療・製薬
◆販売価格オプション（消費税別）

Sigle User	GBP3,499 ⇒換算￥489,860	見積依頼/購入/質問フォーム
Departmental/Five User	GBP3,899 ⇒換算￥545,860	見積依頼/購入/質問フォーム
Site License	GBP4,999 ⇒換算￥699,860	見積依頼/購入/質問フォーム

※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、医薬品卸売/流通の世界市場について調査・分析し、以下の構成でお届けいたします。

・レポートの概要
・イントロダクション
・医薬品卸売/流通の世界市場
　（市場規模予測、市場の成長要因・阻害要因など）
・医薬品卸売/流通の世界市場：地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

Pharma Wholesaling and Distribution – Now Gain Analysis of Companies, Trends and Revenues to Benefit Your Influence
What does the future hold for drug wholesale and distribution (W&D) services? Discover revenue predictions there to 2025. And explore trends in those services and technologies, assessing prospects and finding opportunities to benefit your work and influence.

In visiongain’s new report you gain revenue forecasts at overall world market, submarket, company and national level. That study’s purpose is to show what is possible. There you assess potential for expanding revenues. See where that industry’s best prospects lie.

Read on, then, to explore activities of distributors and wholesalers of pharmaceuticals, discovering what that business’s future could be worth and how it changes.

Forecasts and other analysis to benefit your knowledge of medical distribution systems
Is finding pharma wholesale and distribution information a challenge? Avoid falling behind in knowledge on the supply of medicines. With our data you help your research, analyses and decisions. Also you save time and benefit your reputation for commercial insight.

Besides revenue forecasting, our new investigation shows historical data, growth rates and market shares. That industry changes in 2015 through mergers and acquisitions. So avoid missing out. In our study discover what is happening, helping you stay ahead.

There you find original quantitative and qualitative analyses, exploring business outlooks and developments. You also gain 83 tables, 98 charts and a research interview.

Discover where revenues can increase most. In the following sections you see how our new study benefits your knowledge on the supply chain for human medicines.

Prospects for that world market and submarkets – discover what revenues are possible
Our new report shows revenue to 2025 for the overall world market. It also gives you forecasts for three submarkets for distributing and wholesaling of medicines:
• Original-branded pharmaceuticals – small molecules and biological drugs (biologics)
• Generic prescription drugs (generics)
• Other products related to pharmaceutical supply.

How will the pharmaceutical wholesale and distribution (W&D) market grow? Which parts will prosper most, and why? With our data you assess potential sales and revenue growth.

Our study also discusses what stimulates and restrains storing and distributing of drugs. That analysis helps you identify commercial potentials and consider ways for your business to expand.

You also discover geographical revenue predictions.

Sales potentials for medical wholesale and distribution in leading countries
Developments worldwide expand the pharma W&D market, especially rising demand for medicines in emerging countries. China, India, Russia and Brazil underpin revenue growth.

In developed and developing regions, opportunities for drug wholesalers and other medical suppliers will occur from 2015. Pharmacies also stand to gain. See where, why and how.

Our report shows you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• Germany, France, United Kingdom (UK), Italy and Spain (EU5 group)
• Brazil, Russia, India and China (BRIC nations).

There you discover progress and outlooks. You assess the W&D industry’s future, seeing developments and finding their meaning.

Our analysis shows that highest revenue growth to 2025 will occur in developing countries. Developed markets will expand too. You investigate, also finding top companies’ potentials.

Sales forecasting and other analysis for leading pharma intermediaries
How will prominent companies perform to 2025? Our work shows you individual revenue forecasts for 10 wholesalers and distributors, including these firms:
• McKesson
• Cardinal Health
• AmerisourceBergen
• Walgreens Boots Alliance
• MEDIPAL HOLDINGS
• The PHOENIX Group
• SINOPHARM
• Alfresa Holdings
• Suzuken
• Shanghai Pharmaceutical Holdings.

With our sales predictions you assess top organisations, seeing activities, results, changes and outlooks. You find what is happening, understanding trends, competition, challenges and opportunities.

That way you explore the industry’s future, discovering progress and finding what it means. Our study explains the issues affecting that industry’s present and future.

Forces and changes affecting the supply of pharmaceuticals through distribution networks
Our report explains issues, events and shifts affecting that industry and market from 2015, including these influences:
• Roles of medical wholesalers – activities, changes and prospects
• Revenues, costs and profits – find results, opportunities and sales potentials
• Direct-to-pharmacy (DTP) activities – assess how those developments affect suppliers, clients and the W&D market
• Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
• Technologies and services – progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, payers and patients
• Forward buying, fee-for-service systems and the rise of retail pharmacies.

Our investigation also discusses other aspects of that industry, including these forces:
• Alliance Boots merging with Walgreens, and other mergers and acquisitions – explore the effects of takeovers, partnerships and other deals shaping that industry
• Parallel trade – activities, policies, challenges and effects
• Inventory management agreements, clawbacks, reimbursement and discounts
• Rise of specialty medicines, including biologics, complex generics, vaccines and biosimilars – opportunities for intermediaries, including cold chain distribution networks
• Actions against drug counterfeiting – security of pharmaceutical supply chains
• Changes to regulations and healthcare budgets – policies affecting trade.

That way you assess technological, economic, social and political questions, exploring news and outlooks for the pharmaceutical supply chain. You also analyse that industry’s strengths, weaknesses, opportunities and threats.

Discover what the future holds, seeing what is likely to happen, finding how you can benefit.

Value of the overall pharma W&D market in 2019 – what revenue is possible?
Visiongain forecasts that the pharmaceutical wholesale and distribution industry will achieve revenues of $1,292 billion worldwide in 2019. That market continues to rise.

Wholesale and distribution services will experience steady revenue growth from 2015 to 2025, adapting to driving and restraining forces – changes, opportunities and threats. Find how high that industry’s turnover can go, also seeing what influences revenues and profits.

So discover with our data revenue streams and opportunities for intermediaries in the pharma supply chain. You explore established, emerging and rising companies. Their market holds great potential from 2015 for investments, progress and expansion.

Ways World Pharma Wholesale and Distribution Industry and Market: Trends, Developments and Commercial Predictions 2015-2025 helps
In our new analysis you gain the following knowledge to benefit your work and authority:
• World pharma W&D revenue to 2025 – discover that industry’s overall sales potential
• 3 world-level submarkets’ revenues to 2025 – investigate segments’ potentials, finding the most promising places for developments, investments and sales
• 10 leading companies’ revenues to 2025 – discover forecasts for leading players, seeing how they can develop, compete and succeed
• 11 national market forecasts to 2025 in the Americas, Europe and Asia – find the leading countries for revenues, demand and potential sales growth
• Activities of leading organisations – analyse participants’ results, actions, capabilities, deals, mergers and acquisitions
• Competition and opportunities – explore what shapes that industry’s future, assessing prospects for sustaining and developing business, helping you compete and succeed.

That report, by visiongain’s in-house analysts in the UK, gives knowledge with the purpose of saving you effort and time. You gain data and discussions leading companies depend on.

【レポートの目次】

1. Report Overview
1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
1.2 Pharma Wholesale and Distribution Industry Structure
1.3 Benefits of This Report
1.4 How This Report Delivers
1.5 Main Questions This Report Answers
1.6 Who is This Report For?
1.7 Methods of Research and Analysis
1.8 Frequently Asked Questions (FAQ)
1.9 Some Related Reports
1.10 About Visiongain

2. Introduction to Pharma Wholesale and Distribution
2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
2.1.1 Full-Line Wholesalers (FLWs)
2.1.2 Short-Line Wholesalers (SLWs)
2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
2.2.1 Secondary Wholesalers
2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
2.2.3 Major Wholesalers: Distribute a Large Amount of Products to Generate High Profit
2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
2.2.5 Pharmacy Benefit Managers
2.3 Generating Revenue and Profit
2.3.1 Forward Buying to Avoid Price Increases
2.3.2 Fee-for-Service: A Clear Pricing Structure
2.3.2.1 Inventory Management Agreements
2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
2.3.4 Reimbursement and Wholesalers
2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
2.3.6 Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market, 2015-2025
3.1 The World Pharmaceutical Wholesale and Distribution Market in 2014, Restricted by Government Price Reductions and Generic Substitution
3.2 The Pharmaceutical Wholesale and Distribution: World Market Forecast, 2015-2025
3.3 Branded and Generic Drugs: Revenue vs. Profit, 2015-2025
3.3.1 Branded and Generic Drugs: Revenue Generation, 2014
3.3.2 Branded Drugs: Revenue Forecast, 2015-2025
3.3.3 Generic Drugs: Revenue Forecast, 2015-2025

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2015-2025
4.1 The Leading National Markets: The US Dominates in 2014
4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
4.3 The US Pharma Wholesale and Distribution Market
4.3.1 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
4.3.2 Legislation to Prevent Counterfeit Drugs Can Differ Between States
4.3.3 An Increase in Fee-For-Service Activity
4.3.4 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2015-2025
4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
4.4.1 Difference Between the US and Europe
4.4.2 State-Funded Healthcare and Reimbursement
4.4.3 EU5: Market Forecast, 2015-2025
4.4.4 Germany: Pharma Wholesale and Distribution Market, 2014
4.4.4.1 Healthcare Reform
4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.4.5 France: Pharma Wholesale and Distribution Market, 2014
4.4.5.1 France: Social Security Finance Bill 2014
4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.4.6 Italy: Pharma Wholesale and Distribution Market, 2014
4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.4.7 Spain: Pharma Wholesale and Distribution Market, 2014
4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.4.8 UK: Pharma Wholesale and Distribution Market, 2014
4.4.8.1 Price Cuts in the UK
4.4.8.2 UK: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.5 Japan: Pharma Wholesale and Distribution Market, 2014
4.5.1 Drug Pricing and Performing Fees in Japan
4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.6 China: Pharma Wholesale and Distribution Market, 2014
4.6.1 China: Leading Pharma Wholesale and Distribution Companies, 2014
4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.7 Brazil: Pharma Wholesale and Distribution Market, 2014
4.7.1 Drug Price Controls in Brazil
4.7.2 Brazil: Leading Pharma Wholesale and Distribution Companies, 2014
4.7.3 Brazil: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.8 India: Pharma Wholesale and Distribution Market, 2014
4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.9 Russia: Pharma Wholesale and Distribution Market, 2014
4.9.1 Drug Pricing Controls in Russia
4.9.2 Market Trends in Russia
4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2015-2025
4.10 Conclusion

5. Leading Pharma Wholesalers and Distributors in 2015: Current and Future Performance
5.1 The Leading Pharma Wholesalers and Distribution Companies in 2014
5.2 Revenue vs. Profit
5.3 Leading Pharma Wholesale and Distribution Companies: Grouped Forecasts, 2015-2025
5.4 McKesson: The Oldest and Largest Healthcare Services Company in the US
5.4.1 McKesson: Historical Performance, 2009-2014
5.4.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
5.4.3 McKesson: Revenue Forecast, 2015-2025
5.5 Cardinal Health: The World’s third Largest Pharma Wholesaler
5.5.1 Cardinal Health: Historical Performance, 2010-2014
5.5.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
5.5.3 Cardinal Health: Revenue Forecast, 2015-2025
5.6 AmerisourceBergen: Second Largest Global Pharma Wholesaler and Distributor
5.6.1 AmerisourceBergen: Historical Performance, 2010-2014
5.6.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
5.6.3 AmerisourceBergen: Revenue Forecast, 2015-2025
5.7 Walgreens Boots Alliance: The Largest Drugstore Chain in the US and Global Wholesale and Distribution Network
5.7.1 Walgreens Boots Alliance: Historical Performance, 2010-2014
5.7.2 Acquisitions and Future Strategies of Walgreens Boots Alliance
5.7.3 Walgreens Boots Alliance: Revenue Forecast, 2015-2025
5.8 MEDIPAL HOLDINGS CORPORATION: Japan’s Leading Pharmaceutical Wholesaler
5.8.1 MEDIPAL HOLDINGS CORPORATION: Historical Performance, 2010-2014
5.8.2 Future Strategies of MEDIPAL HOLDINGS CORPORATION: Revised Business Portfolio with Diverse Sources of Earnings
5.8.3 MEDIPAL HOLDINGS CORPORATION: Revenue Forecast, 2015-2025
5.9 The PHOENIX Group: Biggest European Wholesaler
5.9.1 The PHOENIX Group: Historical Performance, 2010-2014
5.9.2 Future Strategies of the PHOENIX Group: Selective Acquisitions
5.9.3 The PHOENIX Group: Revenue Forecast, 2015-2025
5.10 SINOPHARM: The Leading Pharmaceutical Wholesaler and Distributor in China
5.10.1 SINOPHARM: Historical Performance, 2010-2014
5.10.2 Future Strategies of SINOPHARM: Provide Comprehensive Services and Wider Business Coverage
5.10.3 SINOPHARM: Revenue Forecast, 2015-2025
5.11 Alfresa Holdings: Second Largest Pharmaceutical Wholesaler and Distributor in Japan
5.11.1 Alfresa Holdings: Historical Performance, 2010-2014
5.11.2 Future Strategy of Alfresa Holdings: To Focus on Expanding Business Fields and Increasing Footprint
5.11.3 Alfresa Holdings: Revenue Forecast, 2015-2025
5.12 SUZUKEN CO., LTD: The First Nationwide Wholesaler of Japan
5.12.1 SUZUKEN CO., LTD: Historical Performance, 2010-2014
5.12.2 Future Strategies of SUZUKEN CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
5.12.3 SUZUKEN CO., LTD: Revenue Forecast, 2015-2025
5.13 Shanghai Pharmaceuticals Holding: China’s Second Largest Wholesaler
5.13.1 Shanghai Pharmaceuticals Holding: Historical Performance, 2010-2014
5.13.2 Future Strategies of Shanghai Pharma: Expansion of Three Leading Regions in China
5.13.3 Shanghai Pharma: Revenue Forecast, 2015-2025

6. Qualitative Analysis of the Pharma Wholesale and Distribution Market
6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market, 2015
6.1.1 The Insatiable Demand for Drugs: A Recession-Proof Industry?
6.1.2 Wholesalers Do More than Deliver Drugs
6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
6.1.3 Large Companies Dominate the Market
6.1.4 Despite High Revenues, Profit Margins Are Low
6.1.5 Government-Induced Drug Price Pressures Restrict Profits
6.1.6 The Problem of Counterfeit Drugs
6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2015-2025
6.2.1 The Demand for Pharmaceuticals is Increasing
6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue, But Drive Profit Generation
6.2.4 The Promotion of Drug Therapy in the US
6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
6.2.6 Increased Adoption of the DTP Distribution Model
6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
6.2.6.2 DTP in the UK Since 1991
6.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model
6.2.6.4 Further Expansion of the DTP Model
6.2.7 The Threat of Healthcare Budget Cuts
6.2.7.1 Healthcare Budget Cuts in Germany
6.2.7.2 Healthcare Budget Cuts in France
6.2.7.3 Healthcare Budget Cuts in Italy
6.2.7.4 Healthcare Budget Cuts in Spain
6.2.7.5 Healthcare Budget Cuts in the UK
6.2.8 Do Large Pharmacy Chains Pose a Threat?
6.2.8.1 Case Study: Walmart and the $4.0 Prescription Scheme
6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
6.2.9 Does the Diversion and Re-importation of Medicines Pose a Threat to the Industry?
6.2.10 The Threat of Industry Consolidation
6.3 Social, Technological, Economical and Political Factors Influencing the Market, 2015-2025 (STEP Analysis)
6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
6.3.2 Political Factor: Combating Counterfeit Medicines
6.3.2.1 The US and E-Pedigree: Becoming Law in California
6.3.2.2 European Pedigree Legislation
6.3.2.3 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
6.3.2.4 Serialisation for Wholesalers: Opportunity or a Challenge?

7. Research Interview
7.1 Interview with Mr Chris Frost, Sales Director of AAH Pharmaceuticals Ltd. (Celesio UK), Coventry
7.1.1 Current Status and Evolution of Pharma Wholesale and Distribution Market in the UK
7.1.2 Driving Factors of the Pharma Wholesale and Distribution Market in the UK?
7.1.3 Future of the UK Pharma Wholesale and Distribution Market
7.1.4 Celesio UK Accounted for More Than 60% of the Group’s Total Retail Pharmacy Business in 2013
7.1.5 The Outcome of McKesson’s Acquisition of Celesio AG
7.1.6 Prominent Business Segments of Celesio AG in the Future

8. Conclusions from the Research and Analysis
8.1 The Future of the Pharma Wholesale and Distribution Market
8.2 The Leading National Pharma Wholesale and Distribution Markets
8.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
8.4 Trends in the Pharma Wholesale and Distribution Industry
8.4.1 Generics Will Threaten Revenue
8.4.2 Manufacturers Will Deliver More Drugs Directly
8.4.3 There Will Be Greater Demand for Specialty Medicines
8.4.4 Consolidation Will Drive Growth
8.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers’ Costs

List of Tables
Table 1.1 The Global Pharma Wholesale and Distribution Industry and Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Top Company, 2014-2025
Table 1.2 Foreign Currency Exchange Rates to $US, 2014
Table 2.1 Use of DTP Model in the UK, 2014
Table 3.1 Pharmaceutical Wholesale and Distribution: World Market ($bn) Forecast, 2015-2025
Table 3.2 Pharmaceutical Wholesale and Distribution: Branded Drugs, Generic Drugs and Others, Revenue ($bn) Forecasts, AGR (%), CAGR (%) and Market Shares (%), 2015-2025
Table 3.3 Wholesale and Distribution of Branded Drugs: Revenue ($bn) and Market Share (%) Forecast, 2015-2025
Table 3.4 Wholesale and Distribution of Generic Drugs: Revenue ($bn) and Market Share (%) Forecast, 2015-2025
Table 4.1 Pharma Wholesale & Distribution Leading National Markets: Revenues ($bn) and Market Shares (%), 2014
Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2015-2025
Table 4.3 Revenue ($bn) and Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2014
Table 4.4 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.5 Price Controls in Europe, 2014
Table 4.6 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2015-2025
Table 4.7 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.8 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.9 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.10 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.11 UK Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.12 Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2019 and 2025
Table 4.13 Japanese Pharmaceutical Wholesale and Distribution Market: Historical Sales ($bn) and Drug Price Revision Growth (%), 2006-2013
Table 4.14 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.15 Chinese Pharma Wholesale & Distribution: Revenue ($bn) and Market Shares (%) of Leading Companies, 2014
Table 4.16 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.17 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.18 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 4.19 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, AGR (%) and CAGR (%), 2015-2025
Table 5.1 Leading Companies in the Pharmaceutical Wholesale and Distribution Market: Revenues ($bn) and Market Shares (%), 2014
Table 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue Forecasts ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%) for 2014, 2019 and 2025
Table 5.4 McKesson, Distribution Solutions: Services and Customers, 2015
Table 5.5 McKesson, Technology Solutions: Services and Customers, 2015
Table 5.6 McKesson: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2009-2014
Table 5.7 McKesson: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.8 McKesson: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.9 Acquisitions by McKesson, 2007-2014
Table 5.10 McKesson: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2014-2025
Table 5.11 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Operating Earnings ($bn), AGR (%) and CAGR (%), 2009-2014
Table 5.12 Cardinal Health: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.13 Cardinal Health: Operating Earnings ($bn) and Annual Growth (%) Breakdown by Business Segment, 2013-2014
Table 5.14 Cardinal Health: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2014
Table 5.15 Valuable Acquisitions by Cardinal Health and their Line of Business, 2007-2015
Table 5.16 Cardinal Health: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.17 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%) 2010-2014
Table 5.18 AmerisourceBergen: Revenue ($bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.19 AmerisourceBergen: Gross Profit ($bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.20 AmerisourceBergen: Revenue ($bn) and Revenue Share (%) Breakdown by Customer, 2014
Table 5.21 Acquisitions by AmerisourceBergen and their Line of Business, 2007-2013
Table 5.22 AmerisourceBergen: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.23 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit ($bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2014
Table 5.24 Walgreens Boots Alliance: Revenue ($bn), AGR (%), and CAGR (%) Forecast, 2015-2025
Table 5.25 MEDIPAL Holdings: Consolidated Subsidiary Companies, 2014
Table 5.26 MEDIPAL Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2014
Table 5.27 MEDIPAL Holdings: Revenue (¥bn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.28 MEDIPAL Holdings: Operating Income ($bn, ¥bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.29 MEDIPAL Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.30 PHOENIX Group: Subsidiary Companies, 2014
Table 5.31 PHOENIX Group: Historical Revenue (Euro bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (Euro bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2014
Table 5.32 PHOENIX Group: Revenue (Euro bn, $bn), Revenue Share (%) Breakdown by Region, 2014
Table 5.33 PHOENIX Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.34 SINOPHARM Group: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2014
Table 5.35 SINOPHARM Group: Revenue (RMBbn, $bn) and Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.36 SINOPHARM Group: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.37 SINOPHARM Group: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.38 Alfresa Holdings: List of Significant Subsidiaries and Affiliates, 2014
Table 5.39 Alfresa Holdings: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2014
Table 5.40 Alfresa Holdings: Sales Launches in the Manufacturing Business Segment, 2014
Table 5.41 Alfresa Holdings: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.42 Alfresa Holdings: Gross Profit (¥bn, $bn), Gross Profit Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.43 Alfresa Holdings: Targets of the 13-15 Medium-term Management Plan – The Challenge of Reform- Uniting to Climb New Peaks, 2014
Table 5.44 Alfresa Holdings: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.45 SUZUKEN: Historical Revenue (¥bn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (¥bn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2014
Table 5.46 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.47 SUZUKEN: Operating Income (¥bn, $bn), Operating Income Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.48 SUZUKEN: Revenue (¥bn, $bn), Revenue Share (%) Breakdown for Pharmaceuticals Distribution Segment by Region, 2014
Table 5.49 SUZUKEN: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 5.50 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Revenue CAGR (%), Gross Profit (RMBbn, $bn), Gross Profit AGR (%) and Gross Profit CAGR (%), 2010-2014
Table 5.51 Shanghai Pharmaceuticals Holding: Revenue (RMBbn, $bn), Revenue Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.52 Shanghai Pharmaceuticals Holding: Operating Profit (RMBbn, $bn), Operating Profit Share (%) and AGR (%) Breakdown by Business Segment, 2013-2014
Table 5.53 Shanghai Pharmaceuticals Holding: Distribution Revenue (RMBbn, $bn), Distribution Revenue Share (%) Breakdown by Region, 2014
Table 5.54 Shanghai Pharmaceuticals Holding: Revenue ($bn), AGR (%) and CAGR (%) Forecast, 2015-2025
Table 6.1 The Pharmaceutical W&D Market: Strengths and Weaknesses, 2014
Table 6.2 The Pharmaceutical W&D Market: Opportunities and Threats, 2015-2025
Table 6.3 Strengths and Weaknesses of the DTP Distribution Model, 2014
Table 6.4 ITR Ratings and Corresponding Reimbursement Rates, 2014
Table 6.5 Social, Technological, Economic and Political Factors Influencing the Pharmaceutical Wholesale and Distribution Market (STEP Analysis), 2015-2025

List of Figures
Figure 1.1 Forecast Global Population Over the Age of 65 Years (millions), Annual Growth Rate (%), 2015-2025
Figure 1.2 Routes of Drug Distribution, 2015
Figure 2.1 Routes of Drug Distribution, 2015
Figure 3.1 The Global Pharmaceutical Wholesale and Distribution Market: Drivers and Restraints, 2015
Figure 3.2 Pharmaceutical Wholesale and Distribution: World Market ($bn) Forecast, 2015-2025
Figure 3.3 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2014
Figure 3.4 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2019
Figure 3.5 Branded Drugs, Generic Drugs and Others: Market Shares (%), 2025
Figure 3.6 Wholesale and Distribution of Branded Drugs, Generic Drugs and Others: Revenue Forecasts ($bn), 2015-2025
Figure 3.7 Wholesale and Distribution of Branded Drugs: Revenue ($bn) Forecast, 2015-2025
Figure 3.8 Wholesale and Distribution of Generic Drugs: Revenue ($bn) Forecast, 2015-2025
Figure 4.1 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2014
Figure 4.2 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2019
Figure 4.3 Pharma Wholesale & Distribution Leading National Markets: Shares (%), 2025
Figure 4.4 Market Share (%) Breakdown of the US Market: The 3 Leading Companies, 2014
Figure 4.5 US Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.6 US Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015-2025
Figure 4.7 EU5 Pharma Wholesale & Distribution Market Shares (%), 2014, 2019 and 2025
Figure 4.8 EU5 Pharma Wholesale & Distribution Market: Revenue ($bn) Forecasts, 2015-2025
Figure 4.9 EU5 Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.10 German Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.11 German Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.12 French Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.13 French Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015 Figure 4.14 Italian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.15 Italian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.16 Spanish Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.17: Spanish Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.18 UK Pharma Wholesale & Distribution Market: Revenue ($bn), 2015-2025
Figure 4.19 UK Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.20 Percentage of the Population Ages 65+ in the US, Europe, Japan, China and India, 2019 and 2025
Figure 4.21 Japanese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.22 Japanese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.23 Chinese Pharma Wholesale & Distribution: Market Shares (%) of Leading Companies, 2014
Figure 4.24 Chinese Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.25 Chinese Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.26 Brazilian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.27 Brazilian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.28 Pharma Wholesale & Distribution Model in India, 2015
Figure 4.29 Indian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.30 Indian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 4.31 Russian Pharma Wholesale & Distribution Market: Revenue ($bn) Forecast, 2015-2025
Figure 4.32 Russian Pharma Wholesale & Distribution Market: Drivers and Restraints, 2015
Figure 5.1 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2014
Figure 5.2 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2019
Figure 5.3 Leading Pharmaceutical Wholesale and Distribution Companies: Market Shares (%), 2025
Figure 5.4 Leading Pharmaceutical W&D Companies: Drivers and Restraints, 2015
Figure 5.5 McKesson: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2009-2014
Figure 5.6 McKesson: Revenue Share (%) Breakdown by Business Segment, 2014
Figure 5.7 McKesson: Gross Profit Share (%) Breakdown by Business Segment, 2014
Figure 5.8 McKesson: Revenue ($bn) Forecast, 2015-2025
Figure 5.9 McKesson: Drivers and Restraints, 2015-2025
Figure 5.10 Cardinal Health: Historical Revenue ($bn), Revenue AGR (%), Operating Earnings ($bn) and Operating Earnings AGR (%), 2009-2014
Figure 5.11 Cardinal Health: Revenue Share (%) Breakdown by Business Segment, 2014
Figure 5.12 Cardinal Health: Revenue Share (%) Breakdown by Customer, 2014
Figure 5.13 Cardinal Health: Revenue ($bn) Forecast, 2015-2025
Figure 5.14 Cardinal Health: Drivers and Restraints, 2015-2025
Figure 5.15 AmerisourceBergen: Historical Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2010-2014
Figure 5.16 AmerisourceBergen: Revenue Share (%) Breakdown by Business Segment, 2014
Figure 5.17 AmerisourceBergen: Revenue ($bn) Breakdown by Customer, 2014
Figure 5.18 AmerisourceBergen: Revenue ($bn) Forecast, 2015-2025
Figure 5.19 AmerisourceBergen: Drivers and Restraints, 2015-2025
Figure 5.20 Walgreens Boots Alliance: Revenue ($bn), Revenue AGR (%), Gross Profit ($bn) and Gross Profit AGR (%), 2010-2014
Figure 5.21 Walgreens Boots Alliance: Revenue ($bn) Forecast, 2015-2025
Figure 5.22 Alliance Boots: Drivers and Restraints, 2015-2025
Figure 5.23 MEDIPAL Holdings: Historical Revenue (¥bn) Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2010-2014
Figure 5.24 MEDIPAL Holdings: Revenue Share (%) Breakdown by Business Segment, 2014
Figure 5.25 MEDIPAL Holdings: Operating Income Share (%) Breakdown by Business Segment, 2014
Figure 5.26 MEDIPAL Holdings: Revenue ($bn) Forecast, 2015-2025
Figure 5.27 MEDIPAL Holdings: Drivers and Restraints, 2015-2025
Figure 5.28 PHOENIX Group: Historical Revenue (Euro bn), Revenue AGR (%), Gross Profit (Euro bn) and Gross Profit AGR (%), 2010-2014
Figure 5.29 PHOENIX Group: Revenue Share (%) Breakdown by Region, 2014
Figure 5.30 PHOENIX Group: Revenue ($bn) Forecast, 2015-2025
Figure 5.31 PHOENIX Group Drivers and Restraints, 2015-2025
Figure 5.32 SINOPHARM Group: Historical Revenue (RMBbn), Revenue AGR (%), Gross Profit (RMBbn) and Gross Profit AGR (%), 2010-2014
Figure 5.33 SINOPHARM Group: Revenue ($bn) Forecast, 2015-2025
Figure 5.34 SINOPHARM Group: Drivers and Restraints, 2015-2025
Figure 5.35 Alfresa Holdings: Historical Revenue (¥bn), Revenue AGR (%), Gross Profit (¥bn) and Gross Profit AGR (%), 2010-2014
Figure 5.36 Alfresa Holdings: Revenue Share (%) Breakdown by Business Segment, 2014
Figure 5.37 Alfresa Holdings: Gross Profit Share (%) Breakdown by Business Segment, 2014
Figure 5.38 Alfresa Holdings: Revenue ($bn) Forecast, 2015-2025
Figure 5.39 Alfresa Holdings: Drivers and Restraints, 2015-2025
Figure 5.40 SUZUKEN: Historical Revenue (¥bn, $bn), Revenue AGR (%), Gross Profit (¥bn, $bn) and Gross Profit AGR (%), 2010-2014
Figure 5.41 SUZUKEN: Revenue Share (%) Breakdown by Business Segment, 2014
Figure 5.42 SUZUKEN: Operating Income Share (%) Breakdown by Business Segment, 2014
Figure 5.43 SUZUKEN: Revenue Share (%) Breakdown by Region in Japan, 2014
Figure 5.44 SUZUKEN: Revenue ($bn) Forecast, 2015-2025
Figure 5.45 SUZUKEN: Drivers and Restraints, 2015-2025
Figure 5.46 Shanghai Pharmaceuticals Holding: Historical Revenue (RMBbn, $bn), Revenue AGR (%), Gross Profit (RMBbn, $bn) and Gross Profit AGR (%), 2010-2014
Figure 5.47 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Business Segment, 2014
Figure 5.48 Shanghai Pharmaceuticals Holding: Revenue Share (%) Breakdown by Region, 2014
Figure 5.49 Shanghai Pharmaceuticals Holding: Revenue ($bn) Forecast, 2015-2025
Figure 5.50 Shanghai Pharmaceuticals Holding: Drivers and Restraints, 2015-2025
Figure 6.1 Comparison of the Wholesale and DTP Routes of Distribution, 2015
Figure 6.2 Drug Pedigree Legislation: EU vs US, 2014
Figure 8.1 Pharmaceutical Wholesale and Distribution: Global Market Forecasts ($bn) by Submarket, 2015-2025
Figure 8.2 Leading National Pharmaceutical Wholesale and Distribution Markets: Revenue Projections ($bn), 2014, 2019 and 2025
Figure 8.3 Leading Pharmaceutical Wholesale and Distribution Companies: Revenue ($bn) Projections, 2014, 2019 and 2025

【レポートのキーワード】

医薬品卸売、医薬品流通、ブランド医薬品、後発医薬品、製薬

★調査レポート[医薬品卸売/流通の世界市場動向及び予測] ( World Pharma Wholesale and Distribution Industry and Market: Trends, Developments and Commercial Predictions 2015-2025 / VGAIN5102607) 販売に関する免責事項

[医薬品卸売/流通の世界市場動向及び予測] ( World Pharma Wholesale and Distribution Industry and Market: Trends, Developments and Commercial Predictions 2015-2025 / VGAIN5102607) についてEメールでお問い合わせ

◆関連調査資料◆

医薬品卸売・流通の世界市場予測
VGAIN7081165 / visiongain / 2017年6月 / visiongain社が発行した当調査レポートでは、医薬品卸売・流通の世界市場について調査・分析し、医薬品卸売・流通の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。・レポートの概要・イントロダクション・医薬品卸売・流通の世界市場　（市場規模予測、市場動向、市場の成長要因・阻害要因など）・医薬品卸売・流通の世界市場：セグメント別市場分析・医薬品卸売・流通の世界市場：地域別市場分析、市場規模予測・市場環境分析・専門家の見解・主要企業分析...The pharma wholesale and distribution market is estimated at $893.69bn in 2016 and is expected to grow at a CAGR of 6.0% in the first half of the forecast period. The market is expected to grow at a CAGR of 5.2% from 2017-2027. In 2016, the branded drugs submarket held 79.5% share of the pharma wholesale and distribution market. How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector. In this brand new 265-page report you will receive 83 tables and 97 figures – all unavailable elsewhere. The...

医薬品卸売・物流の世界市場予測2016-2026
VGAIN61117 / visiongain / 2016年9月 / 当調査レポートでは、医薬品卸売・物流の世界市場について調査・分析し、医薬品卸売・物流の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。 1. レポート概要 2. 医薬品卸売・物流の概要 3. 医薬品卸売・物流の世界市場：2015-2026 4. 医薬品卸売・物流産業：主要国市場2015-2026 5....Pharma Wholesaling and Distribution – Analysis of Companies, Trends and Future Revenues to Benefit Your Influence What does the future hold for drug wholesale and distribution (W&D) services? Discover revenue predictions there to 2026. And explore trends in those services and technologies, assessing prospects and finding opportunities to benefit your work and authority. In visiongain’s new report you gain revenue forecasts at overall world market, submarket, company and national level. There you assess potentials for expanding revenues. See where that industry’s best prospects lie. Please read on to explore activities of distributors and wholesalers of pharmaceuticals, discovering what that business’s...

世界の医薬品卸売及び流通市場：地域別分析、主要企業分析
VISG409042 / visiongain / 2014年9月 / ...Trends and revenue potentials for distributing and wholesaling of medicines Where’s the drug wholesaler and distribution (W&D) market heading? Discover revenue predictions there to 2024. Also find trends in business and technology, assessing prospects and opportunities to help your work and benefit your influence. In visiongain’s new report you gain sales forecasts there at overall world market, submarket, company and national level. That study’s purpose is to let you hear what’s happening. There you assess potential for expanding revenues. See where that industry’s best prospects lie. Read on, then, to explore drug distribution and discover what its future could be...

ジェネリック医薬品の世界市場予測2016-2026
VGAIN60631 / visiongain / 2016年4月 / 当調査レポートでは、ジェネリック医薬品の世界市場について調査・分析し、以下の構成でお届けいたします。 1. レポート概要 2. ジェネリック医薬品の概要 3. ジェネリック医薬品市場 2016-2026 4. 米国のジェネリック医薬品市場...What can be expected from the Generic Drugs Market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects. Our 306-page report provides 175 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across all the major regional and national generic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market. Forecasts from 2016-2026 and other analyses show...

世界のトップ30医薬品製造受託機関（CMO）
VGAIN5100108 / visiongain / 2015年9月 / ...Contracted drug production – stay ahead now by exploring leading companies’ prospects How are pharma contract manufacturing organisations (CMOs) performing? Visiongain’s updated report shows you their prospects to 2025. You discover that outsourcing industry’s results, trends, opportunities and potentials, also with predicted revenues and profits. Our study analyses 30 top CMOs. There you see how revenues from drug production services can increase. You explore trends, technologies and opportunities shaping that industry. Discover that market’s potential, benefiting your reputation for commercial insight. That way you find analysis on established and emerging companies across the world. Read on, please, to scan the...

医薬品販売業務受託機関（CSO）の世界市場
VGAIN503176 / visiongain / 2015年3月 / 当調査レポートでは、医薬品販売業務受託機関（CSO）の世界市場について調査・分析し、以下の構成でお届けいたします。・レポートの概要・イントロダクション・医薬品販売業務受託の世界市場　（市場規模予測、市場の成長要因・阻害要因など）・主要なサービス分野・セグメント別市場分析・地域別市場分析・市場環境分析・専門家の見解...Outsourced selling of medicines – how to find trends, opportunities and potential revenues What’s the future of outsourcing pharma sales activities? For prescription drugs, get new forecasts for contracted promotional activities. Stay ahead, then, for data. There you explore business results, progress, trends, strategies and predicted revenues. Visiongain’s updated report shows what’s possible for those pharmaceutical services. Avoid missing out on opportunities. Instead explore advances in medical detailing and potential gains for contract sales organisations (CSOs). Please read on, then, to investigate that expanding healthcare industry, seeing what its future could be worth. For that outsourcing you assess expected developments....

ADMET検査（吸収/分布/代謝/排泄/毒性検査）の世界市場：インビトロADMET検査、インビボADMET検査、インシリコADMET検査
VGAIN5102611 / visiongain / 2015年10月 / 当調査レポートでは、ADMET検査（吸収/分布/代謝/排泄/毒性検査）の世界市場について調査・分析し、以下の構成でお届けいたします。・レポートの概要・イントロダクション・ADMET検査の世界市場　（市場規模予測、市場の成長要因・阻害要因など）・ADMET検査の世界市場：セグメント別市場分析　（インビトロADMET検査、インビボADMET検査、インシリコADMET検査）・ADMET検査の世界市場：地域別市場分析、市場規模予測・産業動向・専門家の見解...ADMET Products and Services – Your Guide to Trends and Revenue Potentials The pharma ADMET testing market gains much interest from pharmaceutical companies as they look to implement more-predictive ADMET testing. That finding and many others appear in a new report by visiongain. Absorption, distribution, metabolism, excretion and toxicology (ADMET) testing is an integral part of drug development. Visiongain estimates the ADMET testing market was valued at $5.80bn in 2014, with the majority of revenues being attributed to in vitro testing. Our new report gives you 51 tables, 48 charts and three interviews. Discover the most lucrative areas in that...

ラテンアメリカの製薬市場2015-2025
VGAIN5100112 / visiongain / 2015年9月 / ...What can be expected from the Latin American pharmaceutical market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there. Our 140-page report provides 121 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market. Forecasts from 2015-2025 and other analyses...

子宮内膜症治療薬の世界市場予測・研究開発動向
VGAIN6022518 / visiongain / 2016年2月 / 当調査レポートでは、子宮内膜症治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。・レポート概要・子宮内膜症および子宮内膜症治療の概観・子宮内膜症治療薬の世界市場：地域別市場予測・子宮内膜症治療薬の世界市場：主要な薬剤分析・子宮内膜症治療薬の世界市場：研究開発動向・子宮内膜症治療薬の世界市場：定性分析・専門家の見解・結論 ...Endometriosis Medicines – Your 2016 Guide to Sales Potentials of that Rising, Underserved Female Health Market What does the future hold for treating endometriosis, a common disease? Our new analysis forecasts sales of drugs treating that menstrual cycle disorder. Visiongain’s report gives predictions to 2026 at overall world market, product and national level. Avoid falling behind in data or losing influence. Instead discover what progress, opportunities and increasing revenues endometrial therapies face. There you also explore trends, results, R&D and events, assessing commercial prospects. Read on, then, to explore endometriosis treatments, including hormonal therapy. See below what future revenue that...

OTC医薬品（一般用医薬品）の世界市場
VGAIN4121911 / visiongain / 2014年12月 / 当調査レポートでは、OTC医薬品（一般用医薬品）の世界市場について調査・分析し、レポートサマリー、市場概要、世界市場分析（市場規模、市場予測、促進要因、抑制要因）、セグメント別分析、主要地域別分析、市場環境分析、専門家の見解、主要企業分析、結論などの情報をお届けいたします。...World OTC pharmaceuticals – your guide to technologies, trends and revenues Where is the world OTC pharmaceutical market heading? Visiongain’s new report gives you revenue, trends, opportunities, helping you stay ahead. Our 245-page report provides 154 tables, charts, and graphs. Discover the growing trends of this industry. In particular, our new study lets you assess forecasted sales of the overall world market and at the national and leading manufacturer level. You will see financial results, drivers and restraints, and revenue predictions. Besides revenue forecasts to 2025, this report provides you with market shares, business outlooks, qualitative analyses (including SWOT and...

◆H&Iグローバルリサーチ株式会社のお客様（例）◆